2023 ESC Guidelines for the management of acute coronary syndromes Page 1 2023 ESC
Guidelines for the management of acute coronary syndromes Developed by the task force on …

The American Diabetes Association (ADA)“Standards of Care in Diabetes” includes the
ADA's current clinical practice recommendations and is intended to provide the components …

Background In patients with acute myocardial infarction (MI), therapies that could further
reduce the risk of adverse cardiovascular and metabolic outcomes are needed. Methods In …

OBJECTIVE Ketoacidosis induced by sodium–glucose cotransporter 2 inhibitor (SGLT2i)
treatment has been consistently observed in clinical practice in patients with type 2 diabetes …

Chronic complications of diabetes are due to myriad disorders of numerous metabolic
pathways that are responsible for most of the morbidity and mortality associated with the …

Worsening heart failure (WHF) is a severe and dynamic condition characterized by
significant clinical and hemodynamic deterioration. It is characterized by worsening HF …

The spectrum of cardiorenal and metabolic diseases comprises many disorders, including
obesity, type 2 diabetes (T2D), chronic kidney disease (CKD), atherosclerotic cardiovascular …

The prevalence of kidney disease is increasing rapidly worldwide, reflecting rising rates of
obesity, diabetes, and associated metabolic syndrome (MetS). Chronic kidney disease and …

The kidney proximal tubule is a key organ for human metabolism. The kidney responds to
stress with altered metabolite transformation and perturbed metabolic pathways, an ultimate …

Background Certain antineoplastic therapies are associated with an increased risk of
cardiomyopathy and heart failure (HF). Sodium glucose co-transporter 2 (SGLT2) inhibitors …